Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer
- 1 August 2019
- journal article
- review article
- Published by Elsevier in Autoimmunity Reviews
- Vol. 18 (8) , 805-813
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective studyArthritis Research & Therapy, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiativeAnnals of the Rheumatic Diseases, 2012
- Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody TherapyAmerican Journal of Roentgenology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Treatment of rheumatic diseases in patients with HCV and HIV infectionAutoimmunity Reviews, 2008
- Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4Journal of Clinical Oncology, 2006
- CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.Journal of Experimental Medicine, 1995
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994